Pangaea Oncology
Provides personalized cancer molecular diagnostics R&D and services.
Enterprise value
$66m
Share price
€1.72 PANG.MC
Company register number
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | €12.0m | Post IPO Equity | |
| Total Funding | 000k | ||
Banca March(exited)
Electrica Del Oeste(exited)
Irigen(exited)
Zaragoza Activa(exited)
MIRLING EUROPE(exited)
Projecte Trèvol(exited)
Dexeus University Hospital(exited)
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 24 % | 12 % | (5 %) | 83 % | 78 % | 15 % | 12 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 17 % | 8 % | (27 %) | (13 %) | 4 % | (15 %) | (4 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (44 %) | (14 %) | (62 %) | (58 %) | (8 %) | (15 %) | (5 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Notes (0)
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Pangaea Oncology
EditACQUISITION by Pangaea Oncology Jul 2023
ACQUISITION by Pangaea Oncology Jul 2023